This grant opportunity aims to support innovative investigators from eligible organizations to translate promising research and scientific discoveries into the development of tools, devices, technologies, therapeutics, or interventions, that have the potential to address cancer care across the cancer continuum that will ultimately advance cancer care, lessen the burden of cancer, and improve health outcomes.

CARE Fund congratulates the inaugural grantees in this category, to support implementation, translational, and outcomes research that advance the application of scientific discoveries and technologies or informs how the application of scientific discoveries impact patients and populations. A total of 10 grantees are awarded up to $10,256,298 as follows:

• Dotquant LLC (Principal Investigator: Hongyan Liu, PhD)
  A Three-in-One HER Family Targeted RNA Drug for Breast Cancer
• Fred Hutchinson Cancer Center (Principal Investigator: Heather Greenlee, ND, PhD, MPH; Amanda Fretts, PhD, MPH)
  Partnering with Washington State Tribal Communities to Develop Culturally-Tailored Nutrition Resources and Reduce Cancer Health Disparities
• Seattle Children’s Research Institute (Principal Investigator: Jim Olson, MD, PhD)
  Converting an Immunotherapy Resistance Mechanism into a Vulnerability Using Slow-Release Local Immunotherapy
• Seattle Children’s Research Institute (Principal Investigator: Jonathan Tang, PhD)
  Advanced Platform for Developing Conditionally Stable Sensors and Effectors for Cancer Applications
• Talus Bioscience, Inc. (Principal Investigator: Alex Federation, PhD)
  Development of a Direct Inhibitor of the Brachyury Transcription Factor for Chordoma and Non-Small Cell Lung Cancer
• University of Washington (Principal Investigator: Xiaohu Gao, PhD)
  RNA Therapeutics: Bridging the Gap Between Research and Translation
• University of Washington (Principal Investigator: Peggy Hannon, PhD, MPH)
  Workplace Cancer Prevention and Screening: Scaling Up Connect to Wellness for Employees in Low-Wage Industries Across Washington State
• University of Washington (Principal Investigator: Paul Nghiem, MD, PhD)
  Advancing Merkel Cell Carcinoma Management: Improved Recurrence Detection and New Approaches for Immunotherapy-Refractory Disease
• University of Washington (Principal Investigator: Sarah Psutka, MD, MSc; Cindy Lin, MD, FACSM, FAAPMR)
  Phase II Randomized Controlled Clinical Trial evaluating a Scalable, Personalized Home-Based Activity Intervention with ExerciseRx in Survivors with Nonmuscle-Invasive Bladder Cancer: The EMPOWER Trial
• Wayfinder Biosciences, Inc. (Principal Investigator: David Sparkman-Yager, PhD)
  Developing Novel Small Molecule Therapeutics for MYC-Driven Cancers Using Wayfinder Biosciences’ Proprietary RNA-Drugging Platform